Global Point of Care Testing for Infectious Disease Market Size By Type (Immunological Test, Pathogen Nucleic Acid Test), By Application (Hospital, Clinics), By Region, And Segment Forecasts, 2023 to...

The Global Point of Care (PoC) Testing for Infectious Disease Market was valued at USD 14.2 billion in 2023 and is projected to reach USD 24.8 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2023-2031). The market growth is primarily driven by the increasing prevalence of infectious diseases, the demand for rapid and accurate diagnostic solutions, and the growing adoption of PoC testing in decentralized healthcare settings.

PoC testing for infectious diseases allows for immediate diagnostic results, reducing the time to treatment initiation and improving patient outcomes. With the rising incidence of diseases such as COVID-19, tuberculosis, HIV, malaria, and influenza, healthcare facilities worldwide are investing in rapid, cost-effective, and user-friendly PoC diagnostic solutions.

Market Drivers

1. Rising Prevalence of Infectious Diseases

The increasing global burden of communicable diseases, including respiratory infections, sexually transmitted infections (STIs), and hospital-acquired infections, is driving the demand for rapid diagnostic solutions. The ability of PoC tests to deliver real-time results is crucial for timely disease management and containment.

2. Technological Advancements in PoC Testing

Continuous innovations, including microfluidics, biosensors, and molecular diagnostics, have significantly improved the sensitivity and accuracy of PoC tests. Advancements such as lab-on-a-chip technology and CRISPR-based diagnostics are enhancing test performance and reducing processing times.

3. Increased Adoption of Home-Based and Decentralized Testing

With the shift towards decentralized healthcare, there is a growing preference for at-home PoC testing kits and mobile diagnostic solutions. This trend is further fueled by the COVID-19 pandemic, which accelerated the demand for self-testing and remote monitoring options.

Market Restraints

1. Regulatory Challenges and Approval Processes

Stringent regulatory requirements from organizations such as the FDA, WHO, and CE marking authorities can slow down product approval and commercialization. The need for extensive clinical validation often delays the launch of new PoC testing devices.

2. High Cost of Advanced PoC Diagnostic Solutions

Although PoC tests offer convenience and quick results, molecular and immunoassay-based PoC devices often have high costs, limiting their accessibility in low- and middle-income countries (LMICs). The affordability of PoC testing remains a concern for resource-limited settings.

Market Opportunities

1. Expansion in Emerging Markets

Asia-Pacific, Latin America, and Africa present significant growth opportunities due to increasing healthcare investments, rising awareness about infectious diseases, and government-led initiatives to improve diagnostic accessibility.

2. Development of Multiplex PoC Testing Platforms

Multiplex testing platforms capable of simultaneously detecting multiple infections (e.g., COVID-19, influenza, and RSV in a single test) are gaining traction. These platforms reduce diagnostic complexity, improve efficiency, and offer cost-effective solutions for healthcare providers.

3. Integration of AI and IoT in PoC Testing

The integration of artificial intelligence (AI) and the Internet of Medical Things (IoMT) in PoC diagnostics is streamlining data management, result interpretation, and connectivity with electronic health records (EHRs). AI-driven diagnostic algorithms are enhancing the accuracy of test results and facilitating real-time epidemiological monitoring.

Market Segmentation Insights

Market by Test Type

Molecular Diagnostics (PCR, LAMP, CRISPR-based)

Immunoassays (Lateral Flow Assays, ELISA, FIA)

Microfluidics-Based PoC Tests

Biosensors and Lab-on-a-Chip PoC Solutions

Among these, molecular diagnostics dominated the market in 2023, accounting for over 40% of the total revenue. The rising demand for RT-PCR and isothermal amplification-based PoC tests for COVID-19 and other infectious diseases contributed to this growth.

Market by End-Use

Hospitals & Clinics

Diagnostic Laboratories

Home Care Settings

Pharmacies & Retail Clinics

Research Institutes

The hospital & clinic segment accounted for the largest market share in 2023 due to high patient inflow and the need for rapid bedside diagnostics in emergency and critical care settings. However, the home-care segment is expected to witness the fastest growth, driven by the increasing demand for self-testing kits.

Regional Insights

1. North America

North America held the largest market share in 2023, attributed to:

The high prevalence of infectious diseases such as influenza, tuberculosis, and STIs.

Strong healthcare infrastructure and favorable reimbursement policies.

Rising adoption of AI-driven PoC diagnostics.

2. Europe

Europe follows closely, with growth driven by:

Government initiatives to improve early diagnosis of infectious diseases.

High adoption of decentralized PoC testing in primary care settings.

3. Asia-Pacific

Asia-Pacific is expected to be the fastest-growing region, due to:

Rising healthcare investments in China, India, and Japan.

Increasing prevalence of tuberculosis, HIV/AIDS, and hepatitis.

Expansion of mobile diagnostic laboratories in rural areas.

4. Latin America & Middle East & Africa

These regions present significant growth potential due to:

Expanding healthcare access in remote areas.

Rising government focus on disease surveillance programs.

Competitive Scenario

Key players in the Global PoC Testing for Infectious Disease Market include:

Abbott Laboratories

F. Hoffmann-La Roche Ltd

bioMérieux SA

Siemens Healthineers

Cepheid (Danaher Corporation)

Thermo Fisher Scientific

Quidel Corporation

BD (Becton, Dickinson and Company)

LumiraDx

BinaxNOW

Recent Market Developments

2023: Abbott Laboratories launched a next-generation COVID-19 + Influenza combo PoC test using AI-powered interpretation.

2023: Roche Diagnostics introduced a multiplex PoC PCR platform for the detection of respiratory infections.

2024: Siemens Healthineers partnered with a leading telemedicine provider to develop integrated AI-driven PoC testing solutions.

2025: Quidel Corporation expanded its lateral flow PoC test portfolio to include rapid malaria and dengue diagnostics.

Scope of Work – Global Point of Care Testing for Infectious Disease Market